Furthermore, combinatorial strategies targeting OPN along with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapy) have shown potential in overcoming OPN-driven immune evasion, enhancing anti-tumor immunity. The gene discussed is SPP1; the disease is neoplasm.